{"id":"ga-68-labeled-psma-11-pet","safety":{"commonSideEffects":[{"rate":null,"effect":"Radiation exposure"},{"rate":null,"effect":"Injection site reactions"}]},"_chembl":{"chemblId":"CHEMBL5095039","moleculeType":"Small molecule","molecularWeight":"1029.92"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"PSMA-11 is a small-molecule ligand that targets prostate-specific membrane antigen, a transmembrane protein highly expressed on prostate cancer cells. When labeled with Gallium-68 (Ga-68), a positron-emitting radioisotope, it enables PET imaging to detect and visualize PSMA-positive lesions in patients with prostate cancer. This allows clinicians to identify primary tumors, metastases, and recurrent disease for staging and treatment planning.","oneSentence":"Ga-68 labeled PSMA-11 is a positron emission tomography (PET) imaging agent that binds to prostate-specific membrane antigen (PSMA) on prostate cancer cells to enable detection and localization.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:13:36.262Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Imaging of PSMA-positive lesions in men with prostate cancer"},{"name":"Detection of recurrent prostate cancer"}]},"trialDetails":[{"nctId":"NCT05114746","phase":"PHASE2","title":"Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer in Japan","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2022-01-25","conditions":"Prostate Cancer","enrollment":87},{"nctId":"NCT06288113","phase":"PHASE2","title":"Re-treatment With 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, RE-LuPSMA Trial","status":"RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2024-08-01","conditions":"Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8","enrollment":40},{"nctId":"NCT04987086","phase":"NA","title":"68Ga-PSMA PET in the Renal Cell Carcinoma","status":"RECRUITING","sponsor":"Xijing Hospital","startDate":"2021-06-01","conditions":"Renal Cancer, Metastases, PSMA PET","enrollment":300},{"nctId":"NCT06379217","phase":"PHASE1","title":"NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2024-07-29","conditions":"Metastatic Neuroendocrine Prostate Cancer","enrollment":31},{"nctId":"NCT06216249","phase":"PHASE2","title":"Phase 2 Randomized Trial of Flexible Dosing Schedule of 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer (FLEX-MRT)","status":"RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2024-08-01","conditions":"Prostate Carcinoma, Stage IVB Prostate Cancer American Joint Committee on Cancer (AJCC) v8","enrollment":90},{"nctId":"NCT07455097","phase":"","title":"COMBINED PSMA-PET/CT AND MRI STAGING IN INTERMEDIATE AND HIGH-RISK PATIENTS PROSTATA-CANCER (COMBINE-P)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Heinrich-Heine University, Duesseldorf","startDate":"2026-01-01","conditions":"Intermediate-risk Prostate Cancer, High-risk Prostate Cancer","enrollment":600},{"nctId":"NCT05849298","phase":"PHASE2","title":"A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2024-01-03","conditions":"Prostatic Neoplasm","enrollment":49},{"nctId":"NCT04876651","phase":"PHASE3","title":"The Present Study Aims to Compare Patients Who Receive the Investigational Product (177Lu-DOTA-rosopatamab) Plus Standard of Care, in Comparison to Standard of Care Only","status":"TERMINATED","sponsor":"Telix Pharmaceuticals (Innovations) Pty Ltd","startDate":"2023-08-29","conditions":"Metastatic Prostate Cancer","enrollment":16},{"nctId":"NCT04506567","phase":"PHASE1, PHASE2","title":"Fractionated and Multiple Dose 225Ac-J591 for Progressive mCRPC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Weill Medical College of Cornell University","startDate":"2020-08-18","conditions":"Prostate Cancer","enrollment":60},{"nctId":"NCT05160597","phase":"EARLY_PHASE1","title":"Image-Guided (68Ga-PSMA-11 PET/CT) Prostate Biopsy for the Diagnosis of Prostate Cancer in Men With Prior Negative/Inconclusive Biopsy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2022-01-13","conditions":"Prostate Carcinoma","enrollment":30},{"nctId":"NCT06335914","phase":"NA","title":"Dual PSMA and FDG PET Imaging for Patients With Advanced Prostate Cancer","status":"RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2025-04-03","conditions":"Advanced Prostate Cancer","enrollment":30},{"nctId":"NCT05176223","phase":"PHASE2","title":"68Ga PSMA PET Imaging for the Treatment of Advanced Liver Cancer","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2022-01-30","conditions":"Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8","enrollment":29},{"nctId":"NCT04946370","phase":"PHASE1, PHASE2","title":"Phase I/II Trial of Pembrolizumab and Androgen-receptor Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Weill Medical College of Cornell University","startDate":"2021-08-12","conditions":"Prostate Cancer","enrollment":37},{"nctId":"NCT07381582","phase":"EARLY_PHASE1","title":"Safety, Tolerability and Preliminary Efficacy of 161Tb-LNC1011 (PSMA Radioligand) in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)","status":"NOT_YET_RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2026-01-01","conditions":"Prostate Cancer","enrollment":15},{"nctId":"NCT06145633","phase":"PHASE2","title":"Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2024-09-18","conditions":"Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8","enrollment":15},{"nctId":"NCT07365397","phase":"NA","title":"Imaging Characteristics of Different ⁶⁸Ga-PSMA Probes in Prostate Cancer","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2026-01-19","conditions":"Prostate Cancer","enrollment":9},{"nctId":"NCT07357259","phase":"NA","title":"Delayed Pelvic Imaging With [68]Ga-PSMA PET/CT in a Patient With High-risk Prostate Cancer.","status":"RECRUITING","sponsor":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","startDate":"2025-02-03","conditions":"High-risk Prostate Cancer","enrollment":244},{"nctId":"NCT06444412","phase":"PHASE2","title":"An Investigational Scan (Ga-68 PSMA-11 PET/CT) for Detection of Disease Recurrence or Progression in Patients With Glioma","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2026-01-12","conditions":"WHO Grade 3 Glioma, WHO Grade 4 Glioma","enrollment":25},{"nctId":"NCT06039371","phase":"PHASE2","title":"Supraphysiological Androgen to Enhance Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study","status":"RECRUITING","sponsor":"University of Washington","startDate":"2024-05-21","conditions":"Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8","enrollment":69},{"nctId":"NCT06353321","phase":"","title":"Non-significant Risk (NSR) Study of [68Ga]-PSMA-11 (Illuccix) as a BgRT BioGuide on RefleXion X1","status":"RECRUITING","sponsor":"University of Texas Southwestern Medical Center","startDate":"2024-12-12","conditions":"Prostate Cancer","enrollment":25},{"nctId":"NCT04777071","phase":"PHASE2","title":"An Investigational Scan (68Ga-PSMA-11 PET) for the Imaging of Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Washington","startDate":"2021-05-17","conditions":"Biochemically Recurrent Prostate Carcinoma, Metastatic Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma","enrollment":141},{"nctId":"NCT07324733","phase":"NA","title":"Exploring the Novel Value of PSMA PET in Sjögren's Syndrome: Integrated Analysis With Established FAPI PET Imaging","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2025-09-01","conditions":"Primary Sjögren Syndrome, PET","enrollment":60},{"nctId":"NCT05562791","phase":"PHASE1","title":"A Study of 68Gallium PSMA-PET/CT Scans in People With Bladder Cancer or Skin Cancer","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2022-09-28","conditions":"Bladder Cancer","enrollment":20},{"nctId":"NCT06450548","phase":"NA","title":"Dynamic 68Ga-PSMA and 18F-FDG PET/CT Analysis Prior to 177Lu-PSMA","status":"RECRUITING","sponsor":"Centre Henri Becquerel","startDate":"2025-03-05","conditions":"Prostate Cancer Metastatic","enrollment":60},{"nctId":"NCT07301827","phase":"NA","title":"Study on the Diagnostic Value of Novel PET Molecular Imaging for Renal Cell Carcinoma","status":"RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2025-06-01","conditions":"Renal Cell Carcinoma","enrollment":66},{"nctId":"NCT07150715","phase":"PHASE2","title":"Alpha-Emitting Radionuclide or Beta-Emitting Radionuclide With Metastasis-Directed Stereotactic Body Radiotherapy for the Treatment of Recurrent, Oligometastatic Prostate Adenocarcinoma","status":"RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2025-12-12","conditions":"Oligometastatic Prostate Adenocarcinoma, Recurrent Prostate Adenocarcinoma","enrollment":107},{"nctId":"NCT04176497","phase":"PHASE2","title":"PSMA-PET/MRI Unfavorable-Risk Target Volume Pilot Study","status":"TERMINATED","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2020-07-16","conditions":"Prostate Cancer","enrollment":8},{"nctId":"NCT06209567","phase":"EARLY_PHASE1","title":"A Study of 68Ga-PSMA-11 PET Scans in People With Brain Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2024-01-05","conditions":"High-grade Glioma, Brain Metastases, Brain Metastases, Adult","enrollment":11},{"nctId":"NCT07242014","phase":"NA","title":"68Ga-XACP3 PET/CT in Prostate Cancer","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Xiamen University","startDate":"2025-09-01","conditions":"Prostate Cancer, PET/CT, ACP3","enrollment":60},{"nctId":"NCT05079698","phase":"PHASE1","title":"A Study of Stereotactic Body Radiotherapy and 177Lu-PSMA-617 for the Treatment of Prostate Cancer","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2021-10-01","conditions":"Prostate Cancer","enrollment":27},{"nctId":"NCT06062745","phase":"PHASE1","title":"Pilot Study for Detection of PSMA-Low CRPC-NE Tumors With Fluciclovine PET/CT","status":"RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2024-02-01","conditions":"Advanced Prostate Cancer, Metastatic Prostate Cancer, Metastatic Prostate Neuroendocrine Carcinoma","enrollment":30},{"nctId":"NCT07223034","phase":"PHASE1","title":"A Study of 177Lu-PSMA-617 in People With Gliomas","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2025-10-27","conditions":"Glioma, Diffuse Astrocytoma, IDH-Wildtype (Grade 2-4), Glioblastoma, IDH-wildtype","enrollment":20},{"nctId":"NCT04762888","phase":"PHASE2","title":"68Ga-PSMA-Dual-Contrast PET/MRI or PET/CT for Early Detection of Liver Cancer","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2021-02-24","conditions":"Hepatocellular Carcinoma","enrollment":52},{"nctId":"NCT06999837","phase":"NA","title":"[68Ga]Ga-PSMA PET/CT in Hepatocellular Carcinoma: Impact of Multiparametric Dynamic Whole-body Imaging and Kinetic Modeling.","status":"RECRUITING","sponsor":"Nantes University Hospital","startDate":"2025-09-23","conditions":"HCC - Hepatocellular Carcinoma","enrollment":40},{"nctId":"NCT07209878","phase":"PHASE2, PHASE3","title":"68Ga-PSMA-11 PET Imaging for Diagnosing Prostate Cancer, a Head-to-head Comparison With mpMRI","status":"RECRUITING","sponsor":"First Affiliated Hospital of Fujian Medical University","startDate":"2020-01-10","conditions":"Prostate Cancer (Adenocarcinoma)","enrollment":100},{"nctId":"NCT06265272","phase":"","title":"Value of [68Ga]Ga-PSMA-11 PET/MRI in the Assessment of Liver Cirrhosis","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2023-12-10","conditions":"Liver Cirrhosis, Hepatic Cell Carcinoma, Portal Hypertension","enrollment":45},{"nctId":"NCT06852820","phase":"PHASE2","title":"68Ga-PSMA-11 PET-directed Radioligand Therapy in Metastatic Hepatocellular Carcinoma (HCC)","status":"NOT_YET_RECRUITING","sponsor":"Melissa Lumish","startDate":"2025-09-22","conditions":"Liver Cancer, Hepatocellular Carcinoma, Metastatic Liver Cancer","enrollment":10},{"nctId":"NCT05324332","phase":"NA","title":"68Ga-P16-093 and 68Ga-PSMA-11 PET/CT Imaging in the Same Group of Primary Prostate Cancer Patients","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2022-04-15","conditions":"Prostate Cancer","enrollment":50},{"nctId":"NCT07168616","phase":"","title":"Study of PSMA PET/CT Imaging to Help Select Men With Low-Risk Prostate Cancer for Active Surveillance","status":"RECRUITING","sponsor":"Istanbul University - Cerrahpasa","startDate":"2025-09-01","conditions":"Low Risk Prostate Cancer, Clinically Significant Prostate Cancer","enrollment":201},{"nctId":"NCT04745871","phase":"NA","title":"Diagnostic Performance of PSMA PET/CT for Pre-operative Lymph Node Assessment in Intermediate and High-risk Non-metastasic Prostate Cancer (PREOP-PSMA ).","status":"RECRUITING","sponsor":"University Hospital, Brest","startDate":"2021-05-20","conditions":"Prostate Cancer","enrollment":159},{"nctId":"NCT06521775","phase":"PHASE2","title":"An Investigational Scan (Ga-68 PSMA-11 PET/CT) for the Detection of Therapy Response in Patients With Metastatic Adenoid Cystic Carcinoma","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2024-08-12","conditions":"Metastatic Adenoid Cystic Carcinoma","enrollment":6},{"nctId":"NCT06200103","phase":"PHASE2","title":"Schedule De-Escalation of 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2024-05-03","conditions":"Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8","enrollment":236},{"nctId":"NCT07052214","phase":"PHASE3","title":"PSMA PET Combined With MRI for the Detection of PCa","status":"RECRUITING","sponsor":"Telix Pharmaceuticals (Innovations) Pty Limited","startDate":"2025-08-18","conditions":"PCA, Prostate Cancer, Prostatic Neoplasm","enrollment":204},{"nctId":"NCT04030338","phase":"","title":"Prostate-Specific Membrane Antigen (PSMA) PET Scans in People Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2019-07-19","conditions":"Prostate Cancer, Prostate Neoplasm, Prostate Adenocarcinoma","enrollment":58},{"nctId":"NCT04951817","phase":"NA","title":"68Ga-PSMA PET/CT for Ra223 Assessment","status":"RECRUITING","sponsor":"Chang Gung Memorial Hospital","startDate":"2022-03-02","conditions":"Metastatic Prostate Cancer","enrollment":52},{"nctId":"NCT04576871","phase":"EARLY_PHASE1","title":"Re-treatment 225Ac-J591 for mCRPC","status":"COMPLETED","sponsor":"Weill Medical College of Cornell University","startDate":"2020-10-29","conditions":"Prostate Cancer","enrollment":6},{"nctId":"NCT06359717","phase":"","title":"Prospective Validation of PSMA-RADS","status":"ACTIVE_NOT_RECRUITING","sponsor":"Zagazig University","startDate":"2023-01-01","conditions":"Cancer Prostate","enrollment":477},{"nctId":"NCT04147494","phase":"EARLY_PHASE1","title":"Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2019-11-05","conditions":"Breast Carcinoma, Colon Carcinoma, Esophageal Carcinoma","enrollment":29},{"nctId":"NCT05137561","phase":"PHASE2, PHASE3","title":"Robotic-arm Assisted 68 Ga PSMA PET/CT Guided Prostate Biopsy Versus MR Directed Cognitive Fusion TRUS Guided Prostate Biopsy (PROBIOP)","status":"COMPLETED","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2021-10-25","conditions":"Prostate Cancer, Prostate Neoplasm","enrollment":217},{"nctId":"NCT05581979","phase":"","title":"PSMA-PET Imaging of Salivary Gland Tumours and Other Rare Cancers","status":"COMPLETED","sponsor":"National Cancer Centre, Singapore","startDate":"2022-01-26","conditions":"Salivary Gland Tumor, Rare Malignant Neoplasm","enrollment":4},{"nctId":"NCT05547386","phase":"PHASE3","title":"68Ga-PSMA-11 PET/CT Screening Prior to 177Lu-PSMA-617 Therapy for Patients With Metastatic Castrate Resistant Prostate Cancer","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2022-05-09","conditions":"Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8","enrollment":163},{"nctId":"NCT06059469","phase":"PHASE2","title":"PSMA-PET/CT to Assess the Expression of Specific Membrane Antigen (PSMA) in Patients With Progressive Triple-negative Breast Cancer.","status":"RECRUITING","sponsor":"Jules Bordet Institute","startDate":"2022-05-30","conditions":"TNBC - Triple-Negative Breast Cancer","enrollment":20},{"nctId":"NCT06268418","phase":"","title":"Pre-therapeutic 68Ga-PSMA PET AI Based Dose Prediction for 177Lu-PSMA Targeted Radionuclide Therapy","status":"COMPLETED","sponsor":"Central Hospital, Nancy, France","startDate":"2024-11-30","conditions":"Radionucleide Therapy","enrollment":46},{"nctId":"NCT06067269","phase":"PHASE2","title":"Hormone Therapy (Apalutamide) and Image-guided Stereotactic Body Radiation Therapy for the Treatment of Patients With Prostate Cancer, HEATWAVE Trial","status":"RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2024-03-28","conditions":"Prostate Adenocarcinoma, Stage II Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8","enrollment":95},{"nctId":"NCT06655064","phase":"","title":"Registry to Evaluate Long-Term Outcomes in Patients Who Undergo 68-Ga-PSMA-11 PET/CT Imaging Evaluations","status":"TERMINATED","sponsor":"Telix Pharmaceuticals (Innovations) Pty Limited","startDate":"2025-01-30","conditions":"Prostate Cancer (Adenocarcinoma)","enrollment":120},{"nctId":"NCT07056790","phase":"PHASE1, PHASE2","title":"Research on the Application of 68Ga-PSMA-CYC PET Imaging in the Diagnosis, Staging, and Restaging of Prostate Cancer","status":"RECRUITING","sponsor":"First Affiliated Hospital of Fujian Medical University","startDate":"2025-05-15","conditions":"Prostate CA","enrollment":40},{"nctId":"NCT06659926","phase":"NA","title":"The Radium-select Study","status":"RECRUITING","sponsor":"The Netherlands Cancer Institute","startDate":"2025-02-24","conditions":"mCRPC, Male Urogenital Diseases","enrollment":60},{"nctId":"NCT06560905","phase":"PHASE2","title":"Preoperative Planning With PSMA-PET in Melanoma Surgery Trial","status":"RECRUITING","sponsor":"Royal Marsden NHS Foundation Trust","startDate":"2025-03-11","conditions":"Malignant Melanoma","enrollment":16},{"nctId":"NCT04886986","phase":"PHASE1, PHASE2","title":"Phase I/II 225Ac-J591 Plus 177Lu-PSMA-I&T for Progressive Metastatic Castration Resistant Prostate Cancer","status":"SUSPENDED","sponsor":"Weill Medical College of Cornell University","startDate":"2021-06-30","conditions":"Prostate Cancer","enrollment":48},{"nctId":"NCT05644080","phase":"NA","title":"68Ga/177Lu-PSMA Theranostics in Recurrent Grade 3 and Grade 4 Glioma","status":"RECRUITING","sponsor":"St. Olavs Hospital","startDate":"2023-03-28","conditions":"High Grade Glioma","enrollment":10},{"nctId":"NCT06419348","phase":"EARLY_PHASE1","title":"99mTc-QULIC-5-P1 SPECT Imaging in Patients With Prostate Cancer","status":"RECRUITING","sponsor":"First Affiliated Hospital of Chongqing Medical University","startDate":"2024-05-20","conditions":"Prostate Cancer Stage, PSMA, SPECT","enrollment":30},{"nctId":"NCT03582774","phase":"PHASE3","title":"Multicenter Randomized Trial of 68Ga-PSMA-11 PET/CT Based SRT After Radical Prostatectomy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2018-07-12","conditions":"Recurrent Prostate Carcinoma","enrollment":193},{"nctId":"NCT04484701","phase":"","title":"[68Ga]Ga-PSMA-11 PET/CT in the Assessment of High Risk and Recurrent Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"British Columbia Cancer Agency","startDate":"2021-02-01","conditions":"Prostatic Neoplasm, Prostatic Cancer","enrollment":1574},{"nctId":"NCT05582876","phase":"NA","title":"Multicenter Assessment of Clinical Utility PET / MR With the Use of the Radiotracer 68Ga-PSMA-11 in Therapy Planning Personalized in Patients With Prostate Cancer","status":"RECRUITING","sponsor":"Medical University of Bialystok","startDate":"2023-01-10","conditions":"Prostate Cancer","enrollment":366},{"nctId":"NCT03822845","phase":"PHASE2, PHASE3","title":"Evaluating the Clinical Accuracy of Gallium-68 PSMA PET/CT Imaging in Patients With Biochemical Recurrence of Prostate Cancer","status":"COMPLETED","sponsor":"Michael Graham PhD, MD","startDate":"2019-03-01","conditions":"Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant","enrollment":6},{"nctId":"NCT03768349","phase":"EARLY_PHASE1","title":"PSMA and C-11 Choline PET in Patients With Biochemical Recurrence of Prostate Cancer","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2019-01-03","conditions":"Prostate Cancer","enrollment":250},{"nctId":"NCT06907641","phase":"PHASE2","title":"Comparative Performance of 64Copper [64Cu]-SAR-bis-PSMA vs 68Ga PSMA-11 PET CT for the Detection of Prostate Cancer Recurrence in the Setting of Biochemical Failure Following Radical Prostatectomy","status":"RECRUITING","sponsor":"St Vincent's Hospital, Sydney","startDate":"2024-11-21","conditions":"Prostate Cancer (Post Prostatectomy)","enrollment":50},{"nctId":"NCT06901492","phase":"NA","title":"The Diagnostic Application of PSMAPET/MR in Patients Undergoing Secondary Prostate Puncture","status":"NOT_YET_RECRUITING","sponsor":"Nanjing First Hospital, Nanjing Medical University","startDate":"2025-06-01","conditions":"PSMA PET/CT, Prostate Cancer, MpMRI","enrollment":120},{"nctId":"NCT04794777","phase":"PHASE3","title":"Comparing \"Salvage\" Radiotherapy and Individualized PSMA PET/CT Targeted Treatment in With Relapsing Prostate Cancer","status":"RECRUITING","sponsor":"Stefan Carlsson","startDate":"2018-10-30","conditions":"Prostate Cancer","enrollment":450},{"nctId":"NCT04832958","phase":"PHASE2","title":"Imaging Guided Surgery to Improve the Detection of Lymph Node Metastases in Prostate Cancer Patients","status":"COMPLETED","sponsor":"IRCCS San Raffaele","startDate":"2021-05-15","conditions":"Prostate Cancer","enrollment":81},{"nctId":"NCT06044857","phase":"PHASE1","title":"PSMA PET Response Guided SabR in High Risk Pca","status":"RECRUITING","sponsor":"University of Texas Southwestern Medical Center","startDate":"2024-03-07","conditions":"Prostate Adenocarcinoma","enrollment":20},{"nctId":"NCT06866782","phase":"","title":"European Registry of Next Generation Imaging in Advanced Prostate Cancer","status":"RECRUITING","sponsor":"Fundacio Puigvert","startDate":"2024-09-17","conditions":"Prostate Cancer, Advanced Prostate Cancer, Metastatic Prostate Cancer (mPC)","enrollment":600},{"nctId":"NCT06460454","phase":"","title":"PROnostic Interest of 18F-FDG PET/CT in Patients With Metastatic Castration-resistant Prostate Cancer (mCPRC) Progressing","status":"COMPLETED","sponsor":"Central Hospital, Nancy, France","startDate":"2024-11-01","conditions":"Prostate Cancer","enrollment":100},{"nctId":"NCT06461689","phase":"","title":"Comparison of Changes in Tumor Burden in 68Ga-PSMA-11 PET/CT and 177Lu-PSMA SPECT/CT in Metastatic Castration-resistant Prostate Cancer","status":"COMPLETED","sponsor":"Central Hospital, Nancy, France","startDate":"2024-12-31","conditions":"Prostate Cancer Metastatic","enrollment":80},{"nctId":"NCT05214820","phase":"PHASE2","title":"68Ga-PSMA PET Imaging of Upper Metastatic Gastric Cancers to Determine Eligibility to Endoradiotherapy","status":"RECRUITING","sponsor":"Centre de recherche du Centre hospitalier universitaire de Sherbrooke","startDate":"2022-01-17","conditions":"Upper Digestive Tract Cancer","enrollment":20},{"nctId":"NCT06835244","phase":"","title":"Diagnostic Performance of PET/CT-PSMA in Patients With Non-prostatic PSMA-expressing Neoplasms","status":"ENROLLING_BY_INVITATION","sponsor":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","startDate":"2021-09-17","conditions":"PSMA Positive Tumors or Tumor Tissues, Cancer","enrollment":1000},{"nctId":"NCT06242119","phase":"","title":"Clinical Application of the J-PET Scanner Prototype","status":"RECRUITING","sponsor":"Jagiellonian University","startDate":"2024-03-07","conditions":"Prostate Cancer, Prostatic Hyperplasia, Prostatic Neoplasms","enrollment":25},{"nctId":"NCT05680675","phase":"NA","title":"Dual-Tracer Theranostic PET","status":"COMPLETED","sponsor":"University of Utah","startDate":"2022-12-08","conditions":"Neuroendocrine Tumors, Prostate Cancer","enrollment":50},{"nctId":"NCT03465579","phase":"NA","title":"Mp-3TMRI and 68Ga-PSMA PET/CT Guided Prostate Biopsy and Tumor Node Metastasis (TNM) Staging.","status":"TERMINATED","sponsor":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS","startDate":"2018-05-23","conditions":"68Ga-PSMA PET/CT Guided Prostate Biopsy, Mp-3TMRI Guided Prostate Biopsy, Prostate Cancer","enrollment":261},{"nctId":"NCT04750473","phase":"PHASE1","title":"Fluciclovine and PSMA PET/CT for the Classification and Improved Staging of Invasive Lobular Breast Cancer","status":"COMPLETED","sponsor":"Emory University","startDate":"2021-07-16","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Lobular Carcinoma, Metastatic Breast Lobular Carcinoma","enrollment":20},{"nctId":"NCT06770478","phase":"NA","title":"A Study to Evaluate the Diagnostic Efficacy of 68Ga- MY6349 PET/CT in Patients With Tumours","status":"RECRUITING","sponsor":"Xijing Hospital","startDate":"2024-10-18","conditions":"Tumour of Epithelial Origin, 68Ga-MY6349","enrollment":40},{"nctId":"NCT06769893","phase":"NA","title":"A Study Evaluating the Value of 68Ga-NOTA-RCCB6 PET Imaging for Targeting CD70 in the Clinical Staging, Therapeutic Evaluation, and Restaging of Renal Cell Carcinoma, and Comparing It with 68Ga-PSMA PET/CT Imaging","status":"RECRUITING","sponsor":"Xijing Hospital","startDate":"2024-06-12","conditions":"RCC, Renal Cell Cancer","enrollment":60},{"nctId":"NCT02920229","phase":"NA","title":"68Ga-PSMA HBED-PET/CT in the Evaluation of the Biochemical Relapse in Patients With a History of Prostate Cancer Radically Treated","status":"COMPLETED","sponsor":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS","startDate":"2015-11","conditions":"68Ga-PSMA HBED-PET/CT, Prostate Cancer","enrollment":1230},{"nctId":"NCT03453528","phase":"NA","title":"Investigation of PSMA PET/CT as an Imaging Biomarker in Solid Tumors","status":"COMPLETED","sponsor":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS","startDate":"2017-07-04","conditions":"Prostate-specific Membrane Antigen, mCRPC or Advanced/Metastatic Solid Tumors","enrollment":1225},{"nctId":"NCT03454750","phase":"PHASE2","title":"Radiometabolic Therapy (RMT) With 177Lu PSMA 617 in Advanced Castration Resistant Prostate Cancer (CRPC)","status":"COMPLETED","sponsor":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS","startDate":"2022-10-25","conditions":"Metastatic Castration Resistant Prostate Cancer, 68Ga-PSMA PET/CT Positive","enrollment":143},{"nctId":"NCT06188468","phase":"NA","title":"ImmunoPET Targeting Trophoblast Cell-surface Antigen 2 (Trop-2) in Solid Tumors","status":"COMPLETED","sponsor":"The First Affiliated Hospital of Xiamen University","startDate":"2023-10-01","conditions":"Tumor, Solid Tumor, Positron-Emission Tomography","enrollment":90},{"nctId":"NCT06696326","phase":"NA","title":"A Multicenter Study Evaluating the Diagnostic Value of 68Ga-MY6349 PET/CT for Prostate Cancer","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Xiamen University","startDate":"2024-10-01","conditions":"Positron-Emission Tomography(PET), Prostate Cancer, Trophoblast Cell Surface Antigen 2","enrollment":100},{"nctId":"NCT05079828","phase":"NA","title":"Head-to-head Comparison of 68Ga-PSMA-11 and 18F-PSMA-1007","status":"COMPLETED","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2022-07-07","conditions":"Prostate Cancer","enrollment":100},{"nctId":"NCT04716725","phase":"PHASE2","title":"68Ga-PSMA-11 PET for the Diagnosis of Metastatic Castration Resistant Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Thomas Hope","startDate":"2021-09-28","conditions":"Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer AJCC v8","enrollment":15},{"nctId":"NCT04310540","phase":"EARLY_PHASE1","title":"PSMA PET/MRI or PSMA PET/CT for Evaluation of Liver Cancer","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2020-06-05","conditions":"Hepatocellular Carcinoma","enrollment":42},{"nctId":"NCT06600399","phase":"","title":"Correlation Between Prostate-specific Membrane Antigen Positron Emission Tomography and Arterial Spin Labeling Perfusion Imaging in Glioblastoma","status":"COMPLETED","sponsor":"Lanzhou University Second Hospital","startDate":"2022-10-01","conditions":"Glioblastoma","enrollment":26},{"nctId":"NCT02952469","phase":"EARLY_PHASE1","title":"Biodistribution/Reproducibility Ga-68 PSMA-HBED-CC","status":"COMPLETED","sponsor":"University of Iowa","startDate":"2016-07-14","conditions":"Prostatic Neoplasms","enrollment":22},{"nctId":"NCT03389451","phase":"PHASE2, PHASE3","title":"68Ga PSMA PET for Patients With Biochemical Recurrence of Prostate Cancer","status":"COMPLETED","sponsor":"Michael Graham PhD, MD","startDate":"2018-02-16","conditions":"Prostate Cancer, Prostatic Neoplasm, Prostatic Neoplasms, Castration-Resistant","enrollment":30},{"nctId":"NCT06494696","phase":"","title":"68Ga-PSMA PET/MRI in Conjunction With mpMRI for Evaluating Prospective Prostate Cancer Risk","status":"RECRUITING","sponsor":"Chang Gung Memorial Hospital","startDate":"2024-07-01","conditions":"Prostate Cancer","enrollment":71},{"nctId":"NCT05847348","phase":"PHASE3","title":"68Ga-PSMA-11 Efficacy in Detecting BCR Prostate Cancer in Chinese Patients","status":"RECRUITING","sponsor":"Telix Pharmaceuticals (Innovations) Pty Limited","startDate":"2023-07-19","conditions":"Biochemical Recurrence of Malignant Neoplasm of Prostate, Prostate Cancer, BCR Prostate Carcinoma","enrollment":110},{"nctId":"NCT03327675","phase":"NA","title":"High Precision Imaging of Prostate Specific Membrane Antigen for Personalized Treatment in Prostate Cancer","status":"RECRUITING","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2017-09-22","conditions":"Prostate Cancer","enrollment":188},{"nctId":"NCT06484361","phase":"PHASE2","title":"PET/MRI to Stage Prostate Cancer Patients","status":"RECRUITING","sponsor":"IRCCS San Raffaele","startDate":"2020-09-09","conditions":"Prostate Cancer","enrollment":50},{"nctId":"NCT05420727","phase":"PHASE1","title":"Theranostics in Soft Tissue Sarcoma Using a Vascular Disruption Approach","status":"COMPLETED","sponsor":"John O. Prior","startDate":"2023-02-08","conditions":"Soft Tissue Sarcoma","enrollment":14},{"nctId":"NCT03276572","phase":"PHASE1","title":"Phase I Trial of 225Ac-J591 in Patients With mCRPC","status":"COMPLETED","sponsor":"Weill Medical College of Cornell University","startDate":"2017-10-10","conditions":"Prostate Cancer","enrollment":32},{"nctId":"NCT06437496","phase":"EARLY_PHASE1","title":"68Ga-AAZTA-093 PET/CT: First-in-human Study","status":"RECRUITING","sponsor":"First Affiliated Hospital of Fujian Medical University","startDate":"2024-04-01","conditions":"Malignant Neoplasm of Prostate","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Ga-68 labeled DKFZ-PSMA-11","Ga-68 labeled Glu-NH-CO-NH- Lys(Ahx)-HBED-CC","Ga-68 labeled Glu-urea- Lys(Ahx)-HBED-CC","Ga-68 labeled HBED-CC PSMA"],"phase":"phase_3","status":"active","brandName":"Ga-68 labeled PSMA-11 PET","genericName":"Ga-68 labeled PSMA-11 PET","companyName":"University of California, San Francisco","companyId":"university-of-california-san-francisco","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ga-68 labeled PSMA-11 is a positron emission tomography (PET) imaging agent that binds to prostate-specific membrane antigen (PSMA) on prostate cancer cells to enable detection and localization. Used for Imaging of PSMA-positive lesions in men with prostate cancer, Detection of recurrent prostate cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":3,"withResults":3},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}